ORIC Pharmaceuticals

ORIC Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s lead product candidate, ORIC-101, is a potent and selective small molecule antagonist of the glucocorticoid receptor, which has been linked to resistance to multiple classes of cancer therapeutics across a variety of solid tumors. ORIC’s second product candidate, ORIC-533, is an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens. Beyond these two product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC’s scientific founders, Charles Sawyers, MD, and Scott Lowe, Ph.D., have long records of discovering novel targets in cancer that have led to innovative treatments.

ORIC Pharmaceuticals headquartered in United States, North America, operates in the Biotechnology, Health Care, Pharmaceutical, Biopharma, Therapeutics sector. The company focuses on Biotechnology and has secured $57.1B in funding across 140 round(s). With a team of 51-100 employees, ORIC Pharmaceuticals is actively contributing to advancements in Biotechnology. Their latest funding round, Series B - ORIC Pharmaceuticals, raised $53.0M. Discover more about their projects, partnerships, and impact on our platform.